Wedbush Maintains Neutral on Biogen, Raises Price Target to $225
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsPrice Target
Wedbush analyst Laura Chico maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $212 to $225.
Wedbush analyst Laura Chico maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $212 to $225.